rs864321651
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PM5PP3_Strong
The NM_000018.4(ACADVL):c.1699C>T(p.Arg567Trp) variant causes a missense change. The variant allele was found at a frequency of 0.00000372 in 1,342,862 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R567Q) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000018.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACADVL | NM_000018.4 | c.1699C>T | p.Arg567Trp | missense_variant | 18/20 | ENST00000356839.10 | NP_000009.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ACADVL | ENST00000356839.10 | c.1699C>T | p.Arg567Trp | missense_variant | 18/20 | 1 | NM_000018.4 | ENSP00000349297.5 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 0AN: 145926Hom.: 0 Cov.: 31 FAILED QC
GnomAD4 exome AF: 0.00000372 AC: 5AN: 1342862Hom.: 0 Cov.: 39 AF XY: 0.00000452 AC XY: 3AN XY: 663912
GnomAD4 genome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 145926Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 70878
ClinVar
Submissions by phenotype
Very long chain acyl-CoA dehydrogenase deficiency Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 08, 2022 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 567 of the ACADVL protein (p.Arg567Trp). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with VLCAD deficiency (PMID: 28600779). This variant is also known as c.1633C>T:p.R545W. ClinVar contains an entry for this variant (Variation ID: 219172). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant disrupts the p.Arg567 amino acid residue in ACADVL. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 23480858; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Strand Center for Genomics and Personalized Medicine, Strand Life Sciences Pvt Ltd | - | Though the observed variant has not been reported in a clinical context, an overlapping known missense variant, p.Arg567Gln was found to be associated with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD) and was suggested to be present in the C-terminal region unique to ACADVL and ACAD9. In a cohort study consisting of 13 VLCADD patients, p.Arg567Gln variant was observed in a 6 years old male patient in a compound heterozygous state with p.Gly514Glu variant. Fatty acid oxidation probe assay in patient fibroblast reported elevated C14 , C12 and C16 levels but the patient was asymptomatic.The VLCAD activity assay and immunohistologic staining for VLCAD performed on patient fibroblasts reported that p.Arg567Gln variant caused loss of expression and exhibited partial activity as compared to wild type cells. Moreover, prokaryotic mutagenesis and expression studies done on E.coli revealed that p.Arg567Gln variant markedly decreased VLCAD antigen levels making it deleterious while p.Gly514Glu variant showed normal VLCAD antigen levels [PMID:23480858]. Thus, alteration of Arg-567 in both copies of the gene is likely to play a role severe clinical manifestation. The novel variant Arg567Trp, has a probable but no proven role in the disease manifestation; thus it has been classified as a VUS with a likely role in the observed clinical indication. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at